Clinical Trials Logo

Stage II Multiple Myeloma clinical trials

View clinical trials related to Stage II Multiple Myeloma.

Filter by:

NCT ID: NCT00243035 Terminated - Clinical trials for Refractory Multiple Myeloma

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

Start date: August 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of tipifarnib when given together with bortezomib and to see how well they work in treating patients with relapsed multiple myeloma. Tipifarnib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tipifarnib together with bortezomib may kill more cancer cells.